[go: up one dir, main page]

RU98119950A - MEDICINAL PRODUCT FOR OPTIMIZATION OF SLISE VALIDITY AND STIMULATION OF THE INTESTINAL FUNCTION - Google Patents

MEDICINAL PRODUCT FOR OPTIMIZATION OF SLISE VALIDITY AND STIMULATION OF THE INTESTINAL FUNCTION

Info

Publication number
RU98119950A
RU98119950A RU98119950/14A RU98119950A RU98119950A RU 98119950 A RU98119950 A RU 98119950A RU 98119950/14 A RU98119950/14 A RU 98119950/14A RU 98119950 A RU98119950 A RU 98119950A RU 98119950 A RU98119950 A RU 98119950A
Authority
RU
Russia
Prior art keywords
extracellular
treatment
proteinases
prevention
mixture
Prior art date
Application number
RU98119950/14A
Other languages
Russian (ru)
Other versions
RU2198673C2 (en
Inventor
Мишель Ореман
Original Assignee
ОРЕМАН, Мишель
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9604310A external-priority patent/FR2747045B1/en
Application filed by ОРЕМАН, Мишель filed Critical ОРЕМАН, Мишель
Publication of RU98119950A publication Critical patent/RU98119950A/en
Application granted granted Critical
Publication of RU2198673C2 publication Critical patent/RU2198673C2/en

Links

Claims (8)

1. Фармацевтические и/или диетические композиции, предназначенные для контроля гипервязкости интестинальной, бронхиальной и/или генитальной слизи у человека или животных, отличающиеся тем, что они содержат в качестве активного вещества основную внеклеточную протеиназу типа II, продуцируемую Streptomyces fradiae и способную к избирательному лизису субъединицы А холерного токсина и токсина LТ без того, чтобы была затронута субъединица В, в смеси или в сочетании с инертным, нетоксичным, подходящим с точки зрения физиологии носителем или эксципиентом.1. Pharmaceutical and / or dietary compositions intended to control hyperviscosity of intestinal, bronchial and / or genital mucus in humans or animals, characterized in that they contain, as an active substance, the main extracellular proteinase type II produced by Streptomyces fradiae and capable of selective lysis the cholera toxin and LT toxin subunits A, without the B subunit being affected, in a mixture or in combination with an inert, non-toxic, physiologically acceptable carrier or excipient . 2. Фармацевтические и/или диетические композиции по п. 1, отличающиеся тем, что они содержат в качестве активного вещества основную внеклеточную протеиназу типа II Streptomyces fradiae или смесь такой протеиназы и по меньшей мере двух других внеклеточных протеиназ, продуцируемых Streptomyces fradiae, или одну или несколько протеиназ, аминокислотная последовательность которых на 60% или более совпадает с аминокислотной последовательностью основной внеклеточной протеиназы или смеси внеклеточных протеиназ, в смеси или в сочетании с инертным, нетоксичным, подходящим с точки зрения физиологии носителем или эксципиентом. 2. The pharmaceutical and / or dietary compositions according to claim 1, characterized in that they contain as an active substance the main extracellular proteinase of type II Streptomyces fradiae or a mixture of such proteinase and at least two other extracellular proteinases produced by Streptomyces fradiae, or one or several proteinases whose amino acid sequence is 60% or more identical with the amino acid sequence of the main extracellular proteinase or a mixture of extracellular proteinases, in a mixture or in combination with an inert, non-toxic, suitable physiological carrier or excipient. 3. Применение протеиназ по п. 1 или 2 для получения медикамента, предназначенного для лечения плохого всасывания медикаментов или пищи. 3. The use of proteinases according to claim 1 or 2 for the production of a medicament intended for the treatment of poor absorption of medications or food. 4. Применение внеклеточных протеиназ по п. 1 или 2 для получения медикамента, предназначенного для предупреждения и/или лечения нарушений транзита через кишечник, длительной связи инфекционных микроорганизмов со слизистыми, для облегчения регенерации ворсинок слизистой кишечника, а также для предупреждения и/или лечения язвенных болезней пищеварительного тракта и энтеротоксемий, при одновременном обеспечении регуляции секреции интестинальной, бронхиальной или генитальной слизи. 4. The use of extracellular proteinases according to claim 1 or 2 for the preparation of a medicament intended for the prevention and / or treatment of disorders of transit through the intestines, long-term communication of infectious microorganisms with mucous membranes, to facilitate the regeneration of villi of the intestinal mucosa, and also for the prevention and / or treatment of ulcerative diseases of the digestive tract and enterotoxemia, while ensuring regulation of secretion of intestinal, bronchial or genital mucus. 5. Применение одной или нескольких внеклеточных протеиназ по п. 1 или 2 для получения медикамента, предназначенного для предупреждения и/или лечения нарушений деятельности поджелудочной железы и печеночной недостаточности. 5. The use of one or more extracellular proteinases according to claim 1 or 2 to obtain a medication intended for the prevention and / or treatment of disorders of the pancreas and liver failure. 6. Применение одной или нескольких внеклеточных протеиназ по п. 1 или 2 для получения медикамента, предназначенного для предупреждения и/или лечения инфекционных заболеваний, дисфункций иммунной системы, а также для повышения эффективности вакцинаций. 6. The use of one or more extracellular proteinases according to claim 1 or 2 for the manufacture of a medicament intended for the prevention and / or treatment of infectious diseases, dysfunctions of the immune system, and also to increase the effectiveness of vaccinations. 7. Применение одной или нескольких внеклеточных протеиназ по п. 1 или 2 для получения медикамента, предназначенного для предупреждения и/или лечения гормональной недостаточности и дегенеративных заболеваний, связанных со старением. 7. The use of one or more extracellular proteinases according to claim 1 or 2 for the manufacture of a medicament intended for the prevention and / or treatment of hormonal deficiency and degenerative diseases associated with aging. 8. Применение одной или нескольких внеклеточных протеиназ по п. 1 или 2 для получения диетической композиции для питания ослабленных или страдающих от недоедания пациентов. 8. The use of one or more extracellular proteinases according to claim 1 or 2 for the preparation of a dietary composition for the nutrition of debilitated or malnourished patients.
RU98119950/14A 1996-04-05 1997-04-04 Medicinal preparation for optimization of mucus viscosity and stimulation of intestine function RU2198673C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9604310 1996-04-05
FR9604310A FR2747045B1 (en) 1996-04-05 1996-04-05 NEW MEDICINE OPTIMIZING THE VISCOSITY OF MUCUSES AND IMPROVING THE FUNCTIONING OF THE INTESTIN

Publications (2)

Publication Number Publication Date
RU98119950A true RU98119950A (en) 2000-08-27
RU2198673C2 RU2198673C2 (en) 2003-02-20

Family

ID=9490963

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98119950/14A RU2198673C2 (en) 1996-04-05 1997-04-04 Medicinal preparation for optimization of mucus viscosity and stimulation of intestine function

Country Status (18)

Country Link
US (1) US6440413B1 (en)
EP (1) EP0891189A1 (en)
JP (1) JP4196225B2 (en)
CN (1) CN1168499C (en)
AP (1) AP1018A (en)
AU (1) AU735340B2 (en)
BR (1) BR9708506A (en)
CA (1) CA2251009C (en)
CZ (1) CZ298428B6 (en)
FR (1) FR2747045B1 (en)
HU (1) HUP9902421A3 (en)
NO (1) NO324877B1 (en)
NZ (1) NZ332107A (en)
OA (1) OA10894A (en)
PL (1) PL188157B1 (en)
RU (1) RU2198673C2 (en)
TR (1) TR199801976T2 (en)
WO (1) WO1997037681A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
BRPI0510817A (en) * 2004-05-24 2007-11-20 Novozymes As protease, use of a protease, pharmaceutical composition, and method for treating a disease
GB2430881B (en) * 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
CA2707658A1 (en) 2007-12-04 2009-06-11 Novozymes A/S Protease variants for pharmaceutical use
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904942D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
FR2998450A1 (en) * 2012-11-26 2014-05-30 Dominique Hooreman USE OF AN ENZYMATIC COMPLEX IN FEEDING ANIMAL BREEDING ANIMALS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133579A (en) * 1966-03-09 1968-11-13 Shionogi & Co Process for preparing proteases and enzymatic composition prepared thereby
GB1307516A (en) * 1969-02-21 1973-02-21 M Hooreman Enzymatic products which optimise the viscosity of mucuses and their applications
FR2600340A1 (en) * 1986-06-20 1987-12-24 Hooremam Michel PROCESS FOR THE PRODUCTION OF A NEW PROTEOLYTIC COMPLEX STIMULATING THE ACTIVITY OF PANCREAS AND ITS APPLICATIONS IN ZOOTECHNY
RU2005488C1 (en) * 1992-06-16 1994-01-15 Российская фармацевтическая компания "Фарма" Agent for connective tissue diseases treatment
RU2032744C1 (en) * 1992-08-20 1995-04-10 Производственное объединение "Беллмедпрепараты" Strain streptomyces sp - a producer of rifamycin oxidase and a method of rifamycin oxidase preparing
RU2034924C1 (en) * 1993-03-03 1995-05-10 Акционерное общество "Биотехнология" Strain of streptomyces ornatus - a producer of keratinase

Similar Documents

Publication Publication Date Title
US6475511B2 (en) Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
JP2023103393A (en) Fast-Acting Plant-Derived Pharmaceutical Compounds and Nutraceuticals
KR101122843B1 (en) Sustained improver of muscular fatigue
JP2000514399A (en) How to prevent or treat gastrointestinal damage due to chemotherapy or radiation
AU2263300A (en) Bone resorption suppressing agent
JP7764992B2 (en) Neuropsychological function improving agent containing soybean peptide and/or collagen peptide
RU98119950A (en) MEDICINAL PRODUCT FOR OPTIMIZATION OF SLISE VALIDITY AND STIMULATION OF THE INTESTINAL FUNCTION
US6649590B2 (en) Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof
EP2799074A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
US20020054917A1 (en) Compositions comprising beta glucan and lactoferrin, and methods for their use
RU2198673C2 (en) Medicinal preparation for optimization of mucus viscosity and stimulation of intestine function
US9616095B2 (en) Method and a composition having prophylactic activity against venoms and toxins
KR101488921B1 (en) Mint liquid for improving digestive functions and manufacturing method thereof
CA2575706A1 (en) Vitamin b12 compositions
WO1995008318A2 (en) Medicinal substance with anti-infection properties and for use in the treatment of infertility and protection of pregnancy
KR101331913B1 (en) Bambusae Caulis extracts showing a good therapeutic effect on osteoarthritis and its pharmaceutical compositions containing the same
US12226459B2 (en) Collagen hydrolysate for use in prevention and/or treatment of post intensive care syndrome (pics)
RU2119330C1 (en) Suppository
EP1199073A1 (en) Aminoethanesulfonic acid-containing preparations
US20240316140A1 (en) Composition for liver protection comprising mixture of porcine placenta enzymatic hydrolysate and acid hydrolysate
CA2364984A1 (en) Compositions comprising beta glucan and lactoferrin, and methods for their use
JP2001342127A (en) Intestinally absorbable antiinflmmatory factor- containing immunological substance and application thereof
JP2017149696A (en) Muscular damage healing-promoting composition containing lactoferrin and application method thereof
KR100484597B1 (en) Camellia and extracts for the treatment of gastrointestinal disorders and beverages containing them
CN1105587A (en) Traditional Chinese medicine synergist